Emil Christensen

Emil Christensen

Auto-generated profile, based on publicly available information

Emil Christensen

Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2019 in Journal of Clinical Oncology
Verified
Journal Article
Open access
ECEmil Christensen
Emil Christensen
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
HSHimanshu Sethi
Himanshu Sethi
SSSvetlana Shchegrova
Svetlana Shchegrova
RSRaheleh Salari
Raheleh Salari
LDLars Dyrskjøt
Lars Dyrskjøt
PURPOSE: Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy and during chemotherapy. PATIENTS AND METHODS: We included 68 patients with localized advanced bladder cancer. Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor DNA (ctDNA) by ultra-deep sequencing (median, 105,000×) of plasma DNA. Plasma samples (n = 656) were procured at diagnosis, during chemotherapy, before cystectomy, and during surveillance. Expression profiling was performed for tumor subtype and immune signature analyses. RESULTS: Presence of ctDNA was highly prognostic at diagnosis before chemotherapy (hazard ratio, 29.1; P = .001). After cystectomy, ctDNA analysis correctly identified all patients with metastatic relapse during disease monitoring (100% sensitivity, 98% specificity). A median lead time over radiographic imaging of 96 days was observed. In addition, for high-risk patients (ctDNA positive before or during treatment), the dynamics of ctDNA during chemotherapy was associated with disease recurrence ( P = .023), whereas pathologic downstaging was not. Analysis of tumor-centric biomarkers showed that mutational processes (signature 5) were associated with pathologic downstaging ( P = .024); however, no significant correlation for tumor subtypes, DNA damage response mutations, and other biomarkers was observed. Our results suggest that ctDNA analysis is better associated with treatment efficacy compared with other available methods. CONCLUSION: ctDNA assessment for early risk stratification, therapy monitoring, and early relapse detection in bladder cancer is feasible and provides a basis for clinical studies that evaluate early therapeutic interventions.

16 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLSia Viborg Lindskrog
Sia Viborg Lindskrog
FPFrederik Prip
Frederik Prip
PLPhilippe Lamy
Philippe Lamy
ATAnn Taber
Ann Taber
CGClarice S. Groeneveld
Clarice S. Groeneveld
LDLars Dyrskjøt
Lars Dyrskjøt
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.

1 July 2016 in European Urology
Verified
Journal Article
Closed access
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
INIver Nordentoft
Iver Nordentoft
ECEmil Christensen
Emil Christensen
SHSøren Høyer
Søren Høyer
TRThomas Reinert
Thomas Reinert
LDLars Dyrskjøt
Lars Dyrskjøt

25 September 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ATAnn Taber
Ann Taber
ECEmil Christensen
Emil Christensen
PLPhilippe Lamy
Philippe Lamy
INIver Nordentoft
Iver Nordentoft
FPFrederik Prip
Frederik Prip
LDLars Dyrskjøt
Lars Dyrskjøt
Overtreatment with cisplatin-based chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for predicting response have been implemented in the clinic. Here we perform a comprehensive multi-omics analysis (genomics, transcriptomics, epigenomics and proteomics) of 300 MIBC patients treated with chemotherapy (neoadjuvant or first-line) to identify molecular changes associated with treatment response. DNA-based associations with response converge on genomic instability driven by a high number of chromosomal alterations, indels, signature 5 mutations and/orBRCA2mutations. Expression data identifies the basal/squamous gene expression subtype to be associated with poor response. Immune cell infiltration and high PD-1 protein expression are associated with treatment response. Through integration of genomic and transcriptomic data, we demonstrate patient stratification to groups of low and high likelihood of cisplatin-based response. This could pave the way for future patient selection following validation in prospective clinical trials.

31 March 2020 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
JMJoshua J. Meeks
Joshua J. Meeks
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
BFBishoy M. Faltas
Bishoy M. Faltas
JIJohn Taylor III
John Taylor III
TFThomas W. Flaig
Thomas W. Flaig
LDLars Dyrskjøt
Lars Dyrskjøt

1 June 2017 in European Urology
Verified
Journal Article
Closed access
ECEmil Christensen
Emil Christensen
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
INIver Nordentoft
Iver Nordentoft
SHSøren Høyer
Søren Høyer
KKKirstin van der Keur
Kirstin van der Keur
LDLars Dyrskjøt
Lars Dyrskjøt